Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
79.49
+3.41 (4.48%)
At close: Jun 10, 2025, 4:00 PM
79.46
-0.03 (-0.04%)
After-hours: Jun 10, 2025, 4:04 PM EDT
Nuvalent Employees
Nuvalent had 142 employees as of December 31, 2024. The number of employees increased by 50 or 54.35% compared to the previous year.
Employees
142
Change (1Y)
50
Growth (1Y)
54.35%
Revenue / Employee
n/a
Profits / Employee
-$2,118,704
Market Cap
5.71B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Dec 31, 2021 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NUVL News
- 4 weeks ago - Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - PRNewsWire
- 6 weeks ago - Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PRNewsWire
- 6 weeks ago - Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting - PRNewsWire
- 2 months ago - Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - PRNewsWire
- 2 months ago - Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 - PRNewsWire
- 3 months ago - Nuvalent to Participate in Upcoming March Investor Conferences - PRNewsWire
- 3 months ago - Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 5 months ago - Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones - PRNewsWire